Idenix an MSD Company , Cap Gamma, 1682 Rue de la Valsière , 34189 Montpellier Cedex 4, France.
Oxeltis , Cap Delta, 1682 Rue de la Valsière , 34189 Montpellier Cedex 4, France.
J Med Chem. 2018 Oct 25;61(20):9218-9228. doi: 10.1021/acs.jmedchem.8b00141. Epub 2018 Oct 12.
MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine) is a novel nucleoside analog that displays a differentiated mechanism of action as a nucleoside reverse transcriptase translocation inhibitor (NRTTI) compared to approved NRTIs. Herein, we describe our recent efforts to explore the impact of structural changes to the properties of MK-8591 through the synthesis and antiviral evaluation of carbocyclic derivatives. Synthesized analogs were evaluated for their antiviral activity, and the corresponding triphosphates were synthesized and evaluated in a biochemical assay. 4'-Ethynyl-G derivative (±)-29 displayed a promising IC of 33 nM in a hPBMC cell-based antiviral assay, and its triphosphate (TP), (±)-29-TP, displayed an IC of 324 nM in a biochemical RT-polymerase assay. Improved TP anabolite delivery resulting in improved in vitro potency was achieved by preparing the corresponding phosphoramidate prodrug of single enantiomer 29b, with 6-ethoxy G derivative 34b displaying a significantly improved IC of 3.0 nM, paving the way for new directions for this novel class of nucleoside analogs.
MK-8591(4'-乙炔基-2-氟-2'-脱氧腺苷)是一种新型核苷类似物,与已批准的 NRTIs 相比,它作为核苷逆转录酶易位抑制剂(NRTTI)具有不同的作用机制。在此,我们描述了我们最近通过合成和评估碳环衍生物来探索对 MK-8591 性质的结构变化的影响的努力。合成的类似物进行了抗病毒活性评估,相应的三磷酸酯通过生化测定进行了合成和评估。在基于 hPBMC 细胞的抗病毒测定中,4'-乙炔基-G 衍生物(±)-29 的 IC 为 33 nM,其三磷酸酯(TP)(±)-29-TP 在生化 RT-聚合酶测定中的 IC 为 324 nM。通过制备单对映异构体 29b 的相应磷酰胺酯前药,改善了三磷酸酯前药的代谢物传递,从而提高了体外效力,6-乙氧基 G 衍生物 34b 的 IC 显著改善至 3.0 nM,为这一类新型核苷类似物开辟了新的方向。